{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:14:59Z","timestamp":1790266499460,"version":"4.1.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"DOI":"10.3389\/fnins.2020.00466","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:37:55Z","timestamp":1591162675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington\u2019s Disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Shreaya","family":"Chakroborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredric P.","family":"Manfredsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Dec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace E.","family":"Stutzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahri","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068584","article-title":"Assessment of motor function, sensory motor gating and recognition memory in a novel BACHD transgenic rat model for huntington disease.","volume":"8","author":"Abada","year":"2013","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1097\/00001756-200312020-00010","article-title":"Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo.","volume":"14","author":"Agerman","year":"2003","journal-title":"Neuroreport"},{"key":"B3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1212\/WNL.0000000000000037","article-title":"PET imaging shows loss of striatal PDE10A in patients with Huntington disease.","volume":"82","author":"Ahmad","year":"2014","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1523\/JNEUROSCI.3539-10.2011","article-title":"Differential electrophysiological changes in striatal output neurons in Huntington\u2019s disease.","volume":"31","author":"Andre","year":"2011","journal-title":"J. Neurosci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9068","DOI":"10.1523\/JNEUROSCI.21-22-09068.2001","article-title":"Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain.","volume":"21","author":"Andreeva","year":"2001","journal-title":"J. Neurosci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1212\/wnl.50.1.252","article-title":"Frontal lobe volume in patients with Huntington\u2019s disease.","volume":"50","author":"Aylward","year":"1998","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease.","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.neuron.2016.10.064","article-title":"Phosphodiesterase 10A inhibition improves cortico-basal ganglia function in Huntington\u2019s disease models.","volume":"92","author":"Beaumont","year":"2016","journal-title":"Neuron"},{"key":"B9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/1531-8257(199905)14:3<398::aid-mds1003>3.0.co;2-f","article-title":"Pathophysiology of chorea and bradykinesia in Huntington\u2019s disease.","volume":"14","author":"Berardelli","year":"1999","journal-title":"Mov. Disord."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00317","article-title":"Corticostriatal dysfunction in Huntington\u2019s disease: the basics.","volume":"10","author":"Bunner","year":"2016","journal-title":"Front. Hum. Neurosci."},{"key":"B11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pneurobio.2006.11.001","article-title":"The corticostriatal pathway in Huntington\u2019s disease.","volume":"81","author":"Cepeda","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.expneurol.2008.05.015","article-title":"Adenosine A2A receptor antagonism increases nNOS-immunoreactive neurons in the striatum of Huntington transgenic mice.","volume":"213","author":"Cipriani","year":"2008","journal-title":"Exp. Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/bf00313747","article-title":"Huntington\u2019s chorea\u2013 measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid.","volume":"225","author":"Cramer","year":"1981","journal-title":"J. Neurol."},{"key":"B14","first-page":"431","article-title":"Analysis of neurotransmitter metabolites and adenosine 3\u2019,5\u2019-monophosphate in the CSF of patients with extrapyramidal motor disorders.","volume":"40","author":"Cramer","year":"1984","journal-title":"Adv. Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"10371","DOI":"10.1523\/JNEUROSCI.1592-09.2009","article-title":"Alterations in cortical excitation and inhibition in genetic mouse models of Huntington\u2019s disease.","volume":"29","author":"Cummings","year":"2009","journal-title":"J. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/s0006-8993(01)03000-1","article-title":"Reduced activity and protein expression of NOS in R6\/2 HD transgenic mice: effects of L-NAME on symptom progression.","volume":"919","author":"Deckel","year":"2001","journal-title":"Brain Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s0006-8993(02)02550-7","article-title":"Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington\u2019s disease transgenic mice.","volume":"939","author":"Deckel","year":"2002","journal-title":"Brain Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.coph.2006.08.010","article-title":"Plastic abnormalities in experimental Huntington\u2019s disease.","volume":"7","author":"Di Filippo","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1113\/jphysiol.2012.241018","article-title":"Tonic mGluR5\/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin.","volume":"591","author":"Dvorzhak","year":"2013","journal-title":"J. Physiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.biopsych.2019.12.010","article-title":"Genetic risk underlying psychiatric and cognitive symptoms in Huntington\u2019s Disease.","volume":"87","author":"Ellis","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/hbm.24504","article-title":"Dynamic functional network connectivity in Huntington\u2019s disease and its associations with motor and cognitive measures.","volume":"40","author":"Espinoza","year":"2019","journal-title":"Hum. Brain Mapp."},{"key":"B22","doi-asserted-by":"publisher","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","article-title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase.","volume":"273","author":"Fisher","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1201\/9781420020847-7","author":"Francis","year":"2006","journal-title":"Cyclic Nucleotide Phosphodiesterases in Health and Disease"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013417","article-title":"Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6\/2 mouse model of Huntington\u2019s disease.","volume":"5","author":"Giampa","year":"2010","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1460-9568.2009.06649.x","article-title":"Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6\/2 mouse model of Huntington\u2019s disease.","volume":"29","author":"Giampa","year":"","journal-title":"Eur. J. Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.nbd.2009.02.014","article-title":"Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington\u2019s disease.","volume":"34","author":"Giampa","year":"","journal-title":"Neurobiol. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1093\/hmg\/ddg046","article-title":"Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington\u2019s disease knock-in mice.","volume":"12","author":"Gines","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior.","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00837","article-title":"Phosphodiesterase 9A in brain regulates cGMP signaling independent of nitric-oxide.","volume":"13","author":"Harms","year":"2019","journal-title":"Front. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-e","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. The Huntington\u2019s Disease Collaborative Research Group.","volume":"72","year":"1993","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2019s disease transgenic mice prior to the onset of motor symptoms.","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050717","article-title":"Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease.","volume":"7","author":"Heikkinen","year":"2012","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.neuroscience.2008.08.041","article-title":"Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington\u2019s disease mice.","volume":"157","author":"Hickey","year":"2008","journal-title":"Neuroscience"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fnsyn.2019.00014","article-title":"Major contribution of somatostatin-expressing interneurons and cannabinoid receptors to increased GABA synaptic activity in the striatum of Huntington\u2019s disease mice.","volume":"11","author":"Holley","year":"2019","journal-title":"Front. Synaptic Neurosci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.neuropharm.2017.09.005","article-title":"Electrical stimulation of the hippocampal fimbria facilitates neuronal nitric oxide synthase activity in the medial shell of the rat nucleus accumbens: modulation by dopamine D1 and D2 receptor activation.","volume":"126","author":"Hoque","year":"2017","journal-title":"Neuropharmacology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1111\/j.1460-9568.2004.03796.x","article-title":"Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.","volume":"20","author":"Hu","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","article-title":"The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-py ran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1152\/jn.01056.2014","article-title":"Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington\u2019s disease.","volume":"113","author":"Indersmitten","year":"2015","journal-title":"J. Neurophysiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1152\/jn.2001.86.6.2667","article-title":"Electrophysiological and morphological changes in striatal spiny neurons in R6\/2 Huntington\u2019s disease transgenic mice.","volume":"86","author":"Klapstein","year":"2001","journal-title":"J. Neurophysiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1124\/jpet.111.191353","article-title":"Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.","volume":"341","author":"Kleiman","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.nbd.2012.11.016","article-title":"Phosphodiesterase 10A (PDE10A) localization in the R6\/2 mouse model of Huntington\u2019s disease.","volume":"52","author":"Leuti","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tins.2004.08.008","article-title":"Genetic mouse models of Huntington\u2019s and Parkinson\u2019s diseases: illuminating but imperfect.","volume":"27","author":"Levine","year":"2004","journal-title":"Trends Neurosci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1006\/nbdi.2002.0528","article-title":"Decreased expression of striatal signaling genes in a mouse model of Huntington\u2019s disease.","volume":"9","author":"Luthi-Carter","year":"2000","journal-title":"Hum. Mol. Genet."},{"key":"B44","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/nbdi.2002.0528","article-title":"Pyramidal cell loss in motor cortices in Huntington\u2019s disease.","volume":"10","author":"Macdonald","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1523\/JNEUROSCI.4439-05.2006","article-title":"Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats.","volume":"26","author":"Mallet","year":"2006","journal-title":"J. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1523\/JNEUROSCI.5027-04.2005","article-title":"Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo.","volume":"25","author":"Mallet","year":"2005","journal-title":"J. Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.nbd.2009.09.013","article-title":"Dysregulation of coordinated neuronal firing patterns in striatum of freely behaving transgenic rats that model Huntington\u2019s disease.","volume":"37","author":"Miller","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0306-4522(93)90294-p","article-title":"Compartmental loss of NADPH diaphorase in the neuropil of the human striatum in Huntington\u2019s disease.","volume":"53","author":"Morton","year":"1993","journal-title":"Neuroscience"},{"key":"B49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/7854_2013_250","article-title":"Therapeutic strategies for Huntington\u2019s disease.","volume":"22","author":"Mrzljak","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"B50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.expneurol.2014.10.001","article-title":"Application of neurophysiological biomarkers for Huntington\u2019s disease: evaluating a phosphodiesterase 9A inhibitor.","volume":"263","author":"Nagy","year":"2015","journal-title":"Exp. Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum.","volume":"28","author":"Nishi","year":"2008","journal-title":"J. Neurosci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0306-4522(95)00596-x","article-title":"Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington\u2019s disease.","volume":"72","author":"Norris","year":"1996","journal-title":"Neuroscience"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1460-9568.2008.06157.x","article-title":"Feed-forward excitation of striatal neuron activity by frontal cortical activation of nitric oxide signaling in vivo.","volume":"27","author":"Ondracek","year":"2008","journal-title":"Eur. J. Neurosci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.niox.2018.12.002","article-title":"Age-and sex-related changes in cortical and striatal nitric oxide synthase in the Q175 mouse model of Huntington\u2019s disease.","volume":"83","author":"Padovan-Neto","year":"2019","journal-title":"Nitric Oxide"},{"key":"B55","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1523\/JNEUROSCI.1238-14.2015","article-title":"Facilitation of corticostriatal transmission following pharmacological inhibition of striatal phosphodiesterase 10A: role of nitric oxide-soluble guanylyl cyclase-cGMP signaling pathways.","volume":"35","author":"Padovan-Neto","year":"2015","journal-title":"J. Neurosci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-3-319-58811-7_10","article-title":"Regulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition: implications for the treatment of Parkinson\u2019s Disease.","volume":"17","author":"Padovan-Neto","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.neurobiolaging.2018.01.019","article-title":"Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.","volume":"65","author":"Patel","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"B58","author":"Paxinos","year":"2009","journal-title":"The Rat Brain in Stereotaxic Coordinates."},{"key":"B59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0006-8993(02)03102-5","article-title":"Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington\u2019s disease mutation.","volume":"951","author":"Perez-Severiano","year":"2002","journal-title":"Brain Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington\u2019s disease.","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/bpa.12432","article-title":"Cognitive dysfunction in Huntington\u2019s disease: mechanisms and therapeutic strategies beyond BDNF.","volume":"26","author":"Puigdellivol","year":"2016","journal-title":"Brain Pathol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.bbrc.2016.07.058","article-title":"Striatal synaptic dysfunction and altered calcium regulation in Huntington disease.","volume":"483","author":"Raymond","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function.","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"key":"B64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neuroscience.2005.08.062","article-title":"Hyperactive striatal neurons in symptomatic Huntington R6\/2 mice: variations with behavioral state and repeated ascorbate treatment.","volume":"137","author":"Rebec","year":"2006","journal-title":"Neuroscience"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1523\/JNEUROSCI.22-12-05188.2002","article-title":"Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning.","volume":"22","author":"Reed","year":"2002","journal-title":"J. Neurosci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease.","volume":"85","author":"Reiner","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/mds.25624","article-title":"Striatal parvalbuminergic neurons are lost in Huntington\u2019s disease: implications for dystonia.","volume":"28","author":"Reiner","year":"2013","journal-title":"Mov. Disord."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1212\/wnl.62.3.523-a","article-title":"Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.","volume":"60","author":"Rosas","year":"2003","journal-title":"Neurology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurol."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073664","article-title":"Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington\u2019s disease.","volume":"8","author":"Saavedra","year":"2013","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.neuropharm.2009.11.011","article-title":"Nitric oxide-soluble guanylyl cyclase signaling regulates corticostriatal transmission and short-term synaptic plasticity of striatal projection neurons recorded in vivo.","volume":"58","author":"Sammut","year":"2010","journal-title":"Neuropharmacology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"13221","DOI":"10.1523\/JNEUROSCI.2440-12.2012","article-title":"Relationships between the firing of identified striatal interneurons and spontaneous and driven cortical activities in vivo.","volume":"32","author":"Sharott","year":"2012","journal-title":"J. Neurosci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.1523\/JNEUROSCI.5097-08.2009","article-title":"Different subtypes of striatal neurons are selectively modulated by cortical oscillations.","volume":"29","author":"Sharott","year":"2009","journal-title":"J. Neurosci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"key":"B75","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.tins.2004.08.007","article-title":"GABAergic microcircuits in the neostriatum.","volume":"27","author":"Tepper","year":"2004","journal-title":"Trends Neurosci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1124\/jpet.108.146332","article-title":"Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation.","volume":"328","author":"Threlfell","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.baga.2013.08.001","article-title":"Review: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibition.","volume":"3","author":"Threlfell","year":"2013","journal-title":"Basal Ganglia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027187","article-title":"Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.","volume":"6","author":"Tseng","year":"2011","journal-title":"PLoS One"},{"key":"B79","doi-asserted-by":"publisher","first-page":"8093","DOI":"10.1073\/pnas.110078997","article-title":"Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington\u2019s disease.","volume":"97","author":"Turmaine","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B80","doi-asserted-by":"publisher","first-page":"9045","DOI":"10.1021\/jm3007799","article-title":"Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyr an-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.","volume":"55","author":"Verhoest","year":"2012","journal-title":"J. Med. Chem."},{"key":"B81","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.1021\/jm9015334","article-title":"Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.","volume":"52","author":"Verhoest","year":"2009","journal-title":"J. Med. Chem."},{"key":"B82","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.pneurobio.2009.10.007","article-title":"Nitric oxide neurons and neurotransmission.","volume":"90","author":"Vincent","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"B83","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0072-9752(07)01256-0","article-title":"Neuropathology of Huntington\u2019s disease.","volume":"89","author":"Vonsattel","year":"2008","journal-title":"Handb. Clin. Neurol."},{"key":"B84","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease.","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1523\/JNEUROSCI.4470-03.2004","article-title":"The nitric oxide-guanylyl cyclase signaling pathway modulates membrane activity States and electrophysiological properties of striatal medium spiny neurons recorded in vivo.","volume":"24","author":"West","year":"2004","journal-title":"J. Neurosci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/mds.26007","article-title":"Targets for future clinical trials in Huntington\u2019s disease: what\u2019s in the pipeline?","volume":"29","author":"Wild","year":"2014","journal-title":"Mov. Disord."},{"key":"B87","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0006-8993(82)90385-7","article-title":"Ornithine aminotransferase in Huntington\u2019s disease.","volume":"231","author":"Wong","year":"1982","journal-title":"Brain Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase.","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"key":"B89","doi-asserted-by":"publisher","first-page":"15426","DOI":"10.1523\/JNEUROSCI.1148-12.2012","article-title":"A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.","volume":"32","author":"Yu-Taeger","year":"2012","journal-title":"J. Neurosci."},{"key":"B90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.conb.2017.08.004","article-title":"Striatal synapses, circuits, and Parkinson\u2019s disease.","volume":"48","author":"Zhai","year":"2018","journal-title":"Curr. Opin. Neurobiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease.","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"B92","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/hmg\/ddi014","article-title":"Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington\u2019s disease: neuronal selectivity and potential neuroprotective role of HAP1.","volume":"14","author":"Zucker","year":"2005","journal-title":"Hum. Mol. Genet."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T05:38:01Z","timestamp":1591162681000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fnins.2020.00466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":92,"alternative-id":["10.3389\/fnins.2020.00466"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2020.00466","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"article-number":"466"}}